Park Ha Biological Technology Co., Ltd.
PHH · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $2 | $1 |
| % Growth | -3.1% | 28.1% | 106.2% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $2 | $2 | $1 | $1 |
| % Margin | 91.8% | 87.4% | 73.5% | 66.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $0 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | $1 | $1 | $0 | -$1 |
| % Margin | 33.3% | 48% | 10.3% | -53.8% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | $0 |
| Pre-Tax Income | $1 | $1 | $0 | -$0 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | $0 | $1 | $0 | -$0 |
| % Margin | 20.1% | 34.6% | 10% | -52.1% |
| EPS | 0.018 | 0.033 | 0.007 | -0.019 |
| % Growth | -43.7% | 345.2% | 139.5% | – |
| EPS Diluted | 0.018 | 0.033 | 0.007 | -0.019 |
| Weighted Avg Shares Out | 26 | 26 | 26 | 26 |
| Weighted Avg Shares Out Dil | 26 | 26 | 26 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $1 | $0 | -$0 |
| % Margin | 34.3% | 48.8% | 11.5% | -47.8% |